Literature for grazoprevir (S29.001 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2017
1. Guo,Z., Black,S., Hu,Y., McMonagle,P., Ingravallo,P., Chase,R., Curry,S. and Asante-Appiah,E.
   Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a
   J Biol Chem292, 6202-6212. PubMed  Europe PubMed DOI  I
2016
2. Neelamkavil,S.F., Agrawal,S., Bara,T., Bennett,C., Bhat,S., Biswas,D., Brockunier,L., Buist,N., Burnette,D., Cartwright,M., Chackalamannil,S., Chase,R., Chelliah,M., Chen,A., Clasby,M., Colandrea,V.J., Davies,I.W., Eagen,K., Guo,Z., Han,Y., Howe,J., Jayne,C., Josien,H., Kargman,S., Marcantonio,K., Miao,S., Miller,R., Nolting,A., Pinto,P., Rajagopalan,M., Ruck,R.T., Shah,U., Soriano,A., Sperbeck,D., Velazquez,F., Wu,J., Xia,Y. and Venkatraman,S.
   Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor
   ACS Med Chem Lett7, 111-116. PubMed  Europe PubMed DOI  I
2014
3. Gentile,I., Buonomo,A.R., Borgia,F., Zappulo,E., Castaldo,G. and Borgia,G.
   MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection
   Expert Opin Investig Drugs23, 719-728. PubMed  Europe PubMed DOI  I
4. Manns,M.P., Vierling,J.M., Bacon,B.R., Bruno,S., Shibolet,O., Baruch,Y., Marcellin,P., Caro,L., Howe,A.Y., Fandozzi,C., Gress,J., Gilbert,C.L., Shaw,P.M., Cooreman,M.P., Robertson,M.N., Hwang,P., Dutko,F.J., Wahl,J. and Mobashery,N.
   The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis
   Gastroenterology147, 366-376. PubMed  Europe PubMed DOI  I
5. Shah,U., Jayne,C., Chackalamannil,S., Velazquez,F., Guo,Z., Buevich,A., Howe,J.A., Chase,R., Soriano,A., Agrawal,S., Rudd,M.T., McCauley,J.A., Liverton,N.J., Romano,J., Bush,K., Coleman,P.J., Grise-Bard,C., Brochu,M.C., Charron,S., Aulakh,V., Bachand,B., Beaulieu,P., Zaghdane,H., Bhat,S., Han,Y., Vacca,J.P., Davies,I.W., Weber,A.E. and Venkatraman,S.
   Novel quinoline-based P2-P4 macrocyclic derivatives as pan-genotypic HCV NS3/4a protease inhibitors
   ACS Med Chem Lett5, 264-269. PubMed  Europe PubMed DOI  I
6. Xue,W., Ban,Y., Liu,H. and Yao,X.
   Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis
   J Chem Inf Model54, 621-633. PubMed  Europe PubMed DOI  I
2013
7. Ali,A., Aydin,C., Gildemeister,R., Romano,K.P., Cao,H., Ozen,A., Soumana,D., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
   Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance
   ACS Chem Biol8, 1469-1478. PubMed  Europe PubMed DOI  I
8. Sandhiya,R., Dayshy,A.R., Shanthi,V. and Ramanathan,K.
   Investigation of MK-5172 resistance against R155K NS3/4A protease by molecular simulation approach
   Der Pharm Lett5, 13-20.  I
2012
9. Harper,S., McCauley,J.A., Rudd,M.T., Ferrara,M., DiFilippo,M., Crescenzi,B., Koch,U., Petrocchi,A., Holloway,M.K., Butcher,J.W., Romano,J.J., Bush,K.J., Gilbert,K.F., McIntyre,C.J., Nguyen,K.T., Nizi,E., Carroll,S.S., Ludmerer,S.W., Burlein,C., DiMuzio,J.M., Graham,D.J., McHale,C.M., Stahlhut,M.W., Olsen,D.B., Monteagudo,E., Cianetti,S., Giuliano,C., Pucci,V., Trainor,N., Fandozzi,C.M., Rowley,M., Coleman,P.J., Vacca,J.P., Summa,V. and Liverton,N.J.
   Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor
   ACS Med Chem Lett3, 332-336. PubMed  Europe PubMed DOI  I
10. Romano,K.P., Ali,A., Aydin,C., Soumana,D., Ozen,A., Deveau,L.M., Silver,C., Cao,H., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
    The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
    PLoS Pathog8, e1002832-e1002832. PubMed  Europe PubMed DOI  S  I
11. Summa,V., Ludmerer,S.W., McCauley,J.A., Fandozzi,C., Burlein,C., Claudio,G., Coleman,P.J., DiMuzio,J.M., Ferrara,M., Filippo,M.D., Gates,A.T., Graham,D.J., Harper,S., Hazuda,D.J., Huang,Q., McHale,C., Monteagudo,E., Pucci,V., Rowley,M., Rudd,M.T., Soriano,A., Stahlhut,M.W., Vacca,J.P., Olsen,D.B., Liverton,N.J. and Carroll,S.S.
    MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants
    Antimicrob Agents Chemother58, 4995-4995. PubMed  Europe PubMed DOI  I